tag gain-therapeutics 
PharmaShots
FEBRUARY 17, 2023
Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)
Pharmaceutical Technology
SEPTEMBER 30, 2022
Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Gene therapies for rare inherited diseases are very expensive, as they tend to be the only therapeutic option available to patients and are often curative.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 21, 2021
Vounatsos also insisted that Aduhelm’s price tag has not been a factor discouraging treatment with the drug. billion, with Tecfidera’s decline offset in part by gains for follow-up drug Vumerity (diroximel fumarate), which brought in $121 million. That dragged down Biogen’s overall revenues, which fell 18% to $2.2
Pharmaceutical Technology
APRIL 13, 2023
Released on April 12, the report focuses on bluebird bio’s lovotibeglogene autotemcel and Vertex Pharmaceuticals and CRISPR Therapeutics’ exagamglogene autotemcel or exa-cel and their potential use in treating sickle cell disease. million to achieve $150,000 per QALY gained from a healthcare system perspective.
Pharmaceutical Technology
JUNE 29, 2022
For example, while orphan drug designations have more than doubled in the last decade compared to the previous one, only 16% of therapies with orphan tags have managed to gain FDA approval in some indications. The total number of designations more than doubled during 2010–21 compared to those given in the preceding decade.
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. 52% of RSAs focus on oncology RSAs are predominantly arranged within oncology (52%) since these drugs typically rely on RSAs to gain reimbursement. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.
European Pharmaceutical Review
AUGUST 24, 2022
ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. A key aspect in removing many existing hurdles lies in the linker and conjugation of the two therapeutic modalities while maintaining the properties of the naked antibody.
Expert insights. Personalized for you.
40 
Let's personalize your content